The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research.
The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $31.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.
The global glucagon-such as peptide 1 market is anticipated to experience growth due to the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, is a condition that glucagon-such as peptide 1 medications address, particularly in the context of type 2 diabetes, offering potential benefits such as weight loss and improved blood sugar control. As of January 2022, global diabetes prevalence in individuals aged 20-79 was estimated at 10.5% (536.6 million people), with a projected increase to 12.2% (783.2 million) by 2045, according to the National Library of Medicine. Consequently, the escalating prevalence of diabetes is expected to be a driving force for the glucagon-such as peptide 1 market.
The growth of the glucagon-such as peptide 1 (GLP-1) market is further expected to be fueled by an increasing emphasis on personalized medicine. Personalized medicine involves tailoring prevention, detection, or treatment approaches based on an individual's genetic or protein-related information. This approach enables the customization of GLP-1 formulations and dosages according to the specific needs and preferences of each patient. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. Thus, the growing emphasis on personalized medicine serves as a catalyst for the glucagon-such as peptide 1 (GLP-1) market's expansion.
Technological innovations are emerging as a prominent trend in the global glucagon-such as peptide 1 market. Major companies within the market are introducing novel technologies to maintain their competitive positions. For example, Novo Nordisk A/S, a pharmaceutical company based in Denmark, has launched Wegovy, a groundbreaking once-weekly glucagon-such as peptide 1 therapy designed for weight management. Successfully completing the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile, making it an effective option for individuals struggling with obesity to achieve and sustain weight loss.
Leading companies in the glucagon-such as peptide 1 market are strategically focusing on product innovations, such as the development of oral semaglutide, to ensure their continued market presence. Oral semaglutide is a diabetes management medication delivered in pill form and taken orally. Novo Nordisk India, a healthcare company based in India, introduced oral semaglutide in January 2022. This peptide-in-a-pill formulation represents a groundbreaking advancement in diabetes treatment, providing patients with an oral alternative to injections. The innovation addresses challenges related to peptide degradation in the stomach, enhancing both stability and absorption.
In March 2024, Novo Holdings A/S, an investment company based in Denmark, acquired Catalent Inc. for $16.5 billion. This acquisition is intended to enhance Novo Holdings' presence in the rapidly growing GLP-1 market by utilizing Catalent’s established infrastructure in fill-finish manufacturing. This move aims to increase capacity to meet the rising demand for treatments related to diabetes and weight loss. Catalent Inc. is a biotechnology company located in the United States that specializes in advanced delivery technologies and development solutions for pharmaceuticals.
Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals.
North America was the largest region in the glucagon-such as peptide 1 market in 2024. The regions covered in the glucagon-such as peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glucagon-such as peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Glucagon-like peptide 1 (GLP-1) is a peptide hormone derived from amino acids and produced in the L-cells of the intestinal epithelial endocrine. This hormone is employed in the treatment of diseases such as diabetes and obesity.
The primary product types of glucagon-such as peptide 1 include Trulicity, Ozempic, Victoza, Rybelsus, and others. Trulicity, a prescription medicine administered through injection, is designed to enhance blood sugar levels. Various routes of administration, including oral, parenteral, and others, are utilized in settings such as hospitals, specialty clinics, and more.
The glucagon-such as peptide 1 market research report is one of a series of new reports that provides glucagon-such as peptide 1 market statistics, including glucagon-such as peptide 1 industry global market size, regional shares, competitors with a glucagon-such as peptide 1 market share, detailed glucagon-such as peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-such as peptide 1 industry. This glucagon-such as peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glucagon-such as peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $31.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.
The global glucagon-such as peptide 1 market is anticipated to experience growth due to the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, is a condition that glucagon-such as peptide 1 medications address, particularly in the context of type 2 diabetes, offering potential benefits such as weight loss and improved blood sugar control. As of January 2022, global diabetes prevalence in individuals aged 20-79 was estimated at 10.5% (536.6 million people), with a projected increase to 12.2% (783.2 million) by 2045, according to the National Library of Medicine. Consequently, the escalating prevalence of diabetes is expected to be a driving force for the glucagon-such as peptide 1 market.
The growth of the glucagon-such as peptide 1 (GLP-1) market is further expected to be fueled by an increasing emphasis on personalized medicine. Personalized medicine involves tailoring prevention, detection, or treatment approaches based on an individual's genetic or protein-related information. This approach enables the customization of GLP-1 formulations and dosages according to the specific needs and preferences of each patient. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. Thus, the growing emphasis on personalized medicine serves as a catalyst for the glucagon-such as peptide 1 (GLP-1) market's expansion.
Technological innovations are emerging as a prominent trend in the global glucagon-such as peptide 1 market. Major companies within the market are introducing novel technologies to maintain their competitive positions. For example, Novo Nordisk A/S, a pharmaceutical company based in Denmark, has launched Wegovy, a groundbreaking once-weekly glucagon-such as peptide 1 therapy designed for weight management. Successfully completing the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile, making it an effective option for individuals struggling with obesity to achieve and sustain weight loss.
Leading companies in the glucagon-such as peptide 1 market are strategically focusing on product innovations, such as the development of oral semaglutide, to ensure their continued market presence. Oral semaglutide is a diabetes management medication delivered in pill form and taken orally. Novo Nordisk India, a healthcare company based in India, introduced oral semaglutide in January 2022. This peptide-in-a-pill formulation represents a groundbreaking advancement in diabetes treatment, providing patients with an oral alternative to injections. The innovation addresses challenges related to peptide degradation in the stomach, enhancing both stability and absorption.
In March 2024, Novo Holdings A/S, an investment company based in Denmark, acquired Catalent Inc. for $16.5 billion. This acquisition is intended to enhance Novo Holdings' presence in the rapidly growing GLP-1 market by utilizing Catalent’s established infrastructure in fill-finish manufacturing. This move aims to increase capacity to meet the rising demand for treatments related to diabetes and weight loss. Catalent Inc. is a biotechnology company located in the United States that specializes in advanced delivery technologies and development solutions for pharmaceuticals.
Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals.
North America was the largest region in the glucagon-such as peptide 1 market in 2024. The regions covered in the glucagon-such as peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glucagon-such as peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Glucagon-like peptide 1 (GLP-1) is a peptide hormone derived from amino acids and produced in the L-cells of the intestinal epithelial endocrine. This hormone is employed in the treatment of diseases such as diabetes and obesity.
The primary product types of glucagon-such as peptide 1 include Trulicity, Ozempic, Victoza, Rybelsus, and others. Trulicity, a prescription medicine administered through injection, is designed to enhance blood sugar levels. Various routes of administration, including oral, parenteral, and others, are utilized in settings such as hospitals, specialty clinics, and more.
The glucagon-such as peptide 1 market research report is one of a series of new reports that provides glucagon-such as peptide 1 market statistics, including glucagon-such as peptide 1 industry global market size, regional shares, competitors with a glucagon-such as peptide 1 market share, detailed glucagon-such as peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-such as peptide 1 industry. This glucagon-such as peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glucagon-such as peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Glucagon-like Peptide 1 Market Characteristics3. Glucagon-like Peptide 1 Market Trends and Strategies4. Glucagon-like Peptide 1 Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Glucagon-like Peptide 1 Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Glucagon-like Peptide 1 Market34. Recent Developments in the Glucagon-like Peptide 1 Market
5. Global Glucagon-like Peptide 1 Growth Analysis and Strategic Analysis Framework
6. Glucagon-like Peptide 1 Market Segmentation
7. Glucagon-like Peptide 1 Market Regional and Country Analysis
8. Asia-Pacific Glucagon-like Peptide 1 Market
9. China Glucagon-like Peptide 1 Market
10. India Glucagon-like Peptide 1 Market
11. Japan Glucagon-like Peptide 1 Market
12. Australia Glucagon-like Peptide 1 Market
13. Indonesia Glucagon-like Peptide 1 Market
14. South Korea Glucagon-like Peptide 1 Market
15. Western Europe Glucagon-like Peptide 1 Market
16. UK Glucagon-like Peptide 1 Market
17. Germany Glucagon-like Peptide 1 Market
18. France Glucagon-like Peptide 1 Market
19. Italy Glucagon-like Peptide 1 Market
20. Spain Glucagon-like Peptide 1 Market
21. Eastern Europe Glucagon-like Peptide 1 Market
22. Russia Glucagon-like Peptide 1 Market
23. North America Glucagon-like Peptide 1 Market
24. USA Glucagon-like Peptide 1 Market
25. Canada Glucagon-like Peptide 1 Market
26. South America Glucagon-like Peptide 1 Market
27. Brazil Glucagon-like Peptide 1 Market
28. Middle East Glucagon-like Peptide 1 Market
29. Africa Glucagon-like Peptide 1 Market
30. Glucagon-like Peptide 1 Market Competitive Landscape and Company Profiles
31. Glucagon-like Peptide 1 Market Other Major and Innovative Companies
35. Glucagon-like Peptide 1 Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Glucagon-like Peptide 1 Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on glucagon-like peptide 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for glucagon-like peptide 1? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glucagon-like peptide 1 market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Trulicity; Ozempic; Victoza; Rybelsus; Other Types2) By Route of Administration: Oral; Parenteral; Other Routes
3) By End-Users: Hospitals; Specialty Clinics; Other End Users
Subsegments:
1) By Trulicity: Injection (pre-filled pen); Dosage forms (0.75 mg, 1.5 mg, etc.)2) By Ozempic: Injection (pre-filled pen); Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen); Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations; Combination products with other medications; Alternative delivery systems
Key Companies Mentioned: Novo Nordisk AS; Sanofi SA; Eli Lilly and Co; AstraZeneca plc; Pfizer Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novo Nordisk AS
- Sanofi SA
- Eli Lilly and Co
- AstraZeneca plc
- Pfizer Inc
- Boehringer Ingelheim International GmbH
- F Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Baxter
- Hikma Pharmaceuticals plc
- Zealand Pharma A/S
- Intarcia Therapeutics Inc.
- GlaxoSmithKline plc
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Shanghai Benemae Pharmaceutical Corporation
- Adocia
- Biocon
- Hanmi Pharmaceutical Co Ltd
- Ligand Pharmaceuticals Incorporated
- Advinus Therapeutics Ltd
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo Company Limited
- Sun Pharmaceutical Industries Ltd
- Union Chimique Belge
- Amylin Pharmaceuticals LLC
- Academic Pharmaceuticals Inc
- ConjuChem Biotechnologies
- MannKind Corporation:
- Provention Bio Inc
- Regeneron Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 22.37 Billion |
| Forecasted Market Value ( USD | $ 31.27 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
